Skip to main content

Advertisement

SpringerLink
Log in

Everolimus in kidney transplant recipients at high cardiovascular risk: a narrative review

  • Review
  • Published:
Journal of Nephrology Aims and scope Submit manuscript

Abstract

Kidney transplant recipients (KTRs) are at increased risk of cardiovascular (CV) morbidity and mortality, and side effects induced by immunosuppressive therapy may be a major contributor to this risk, together with traditional CV risk factors. Many strategies have been considered in order to reduce CV risk in KTRs, such as steroid and/or calcineurin inhibitor (CNI) minimization, but current data are inconclusive. The introduction of mammalian target of rapamycin (mTOR) inhibitors, the cornerstone of CNI minimization, in the immunosuppressive protocol may reduce both the incidence and severity of CNI-associated side effects; however, whether this strategy has an impact on CV risk after kidney transplantation needs to be evaluated. To this end, a panel of Italian experts in the field of transplantation was convened in a series of meetings to assess the current literature on the potential of the mTOR inhibitor everolimus as a cardioprotective agent. This narrative review summarizes the panel’s round-table discussions and provides recommendations for CV risk management in KTRs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Collins AJ, Foley RN, Chavers B et al (2014) United States Renal Data System 2013 annual data report: atlas of chronic kidney disease & end-stage renal disease in the United States. Am J Kidney Dis 63(Suppl 1):e1

    Google Scholar 

  2. Ojo AO (2006) Cardiovascular complications after renal transplantation and their prevention. Transplantation 82:603–611

    PubMed  Google Scholar 

  3. Gillis KA, Patel RK, Jardine AG (2014) Cardiovascular complications after transplantation: treatment options in solid organ recipients. Transplant Rev (Orlando) 28:47–55

    Google Scholar 

  4. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group (2009) KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 9(Suppl 3):S1–S155

    Google Scholar 

  5. Liefeldt L, Budde K (2010) Risk factors for cardiovascular disease in renal transplant recipients and strategies to minimize risk. Transpl Int 23:1191–1204

    PubMed  Google Scholar 

  6. Jardine AG, Gaston RS, Fellstrom BC, Holdaas H (2011) Prevention of cardiovascular disease in adult recipients of kidney transplants. Lancet 378:1419–1427

    PubMed  Google Scholar 

  7. Zhang W, Fung J (2017) Limitations of current liver transplant immunosuppressive regimens: renal considerations. Hepatobiliary Pancreat Dis Int 16:27–32

    PubMed  Google Scholar 

  8. Knight SR, Morris PJ (2010) Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis. Transplantation 15(89):1–14

    Google Scholar 

  9. Chadban SJ, Eris JM, Kanellis J et al (2014) A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients. Transpl Int 27:302–311

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Montagnino G, Sandrini S, Casciani C et al (2005) A randomized trial of steroid avoidance in renal transplant patients treated with everolimus and cyclosporine. Transplant Proc 37:788–790

    CAS  PubMed  Google Scholar 

  11. Muntner P, He J, Hamm L et al (2002) Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 13:745–753

    PubMed  Google Scholar 

  12. Henry RM, Kostense PJ, Bos G et al (2002) Mild renal insufficiency is associated with increased cardiovascular mortality: the Hoorn Study. Kidney Int 62:1402–1407

    PubMed  Google Scholar 

  13. Abbott KC, Yuan CM, Taylor AJ, Cruess DF, Agodoa LY (2003) Early renal insufficiency and hospitalized heart disease after renal transplantation in the era of modern immunosuppression. J Am Soc Nephrol 14:2358–2365

    PubMed  Google Scholar 

  14. Meier-Kriesche HU, Baliga R, Kaplan B (2003) Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 75:1291–1295

    PubMed  Google Scholar 

  15. Soveri I, Holdaas H, Jardine A, Gimpelewicz C, Staffler B, Fellström B (2006) Renal transplant dysfunction—importance quantified in comparison with traditional risk factors for cardiovascular disease and mortality. Nephrol Dial Transplant 21:2282–2289

    PubMed  Google Scholar 

  16. Weiner DE, Carpenter MA, Levey AS et al (2012) Kidney function and risk of cardiovascular disease and mortality in kidney transplant recipients: the FAVORIT trial. Am J Transplant 12:2437–2445

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Jardine AG, Fellstrom B, Logan JO et al (2005) Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study. Am J Kidney Dis 46:529–536

    PubMed  Google Scholar 

  18. Israni AK, Snyder JJ, Skeans MA, PORT Investigators et al (2010) Predicting coronary heart disease after kidney transplantation: patient outcomes in renal transplantation (PORT) study. Am J Transplant 10:338–353

    CAS  PubMed  Google Scholar 

  19. Issa N, Kukla A, Ibrahim HN (2013) Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence. Am J Nephrol 37:602–612

    CAS  PubMed  Google Scholar 

  20. Nankivell B, Richard J, Borrows R et al (2003) The natural history of chronic allograft nephropathy. N Engl J Med 349:2326–2333

    CAS  PubMed  Google Scholar 

  21. Nankivell B, PʼNg CH, OʼConnell PJ, Chapman JR (2016) Calcineurin inhibitor nephrotoxicity through the lens of longitudinal histology: comparison of cyclosporine and tacrolimus eras. Transplantation 100:1723–1731

    CAS  PubMed  Google Scholar 

  22. Webster A, Woodroffe RC, Taylor RS, Chapman JR, Craig JC (2005) Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev 4:CD003961

    Google Scholar 

  23. Cosio FG, Kudva Y, van der Velde M et al (2005) New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int 67:2415–2421

    PubMed  Google Scholar 

  24. Wauters RP, Cosio FG, Suarez Fernandez ML et al (2012) Cardiovascular consequences of new-onset hyperglycemia after kidney transplantation. Transplantation 94:377–382

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Lentine KL, Brennan DC, Schnitzler MA (2005) Incidence and predictors of myocardial infarction after kidney transplantation. J Am Soc Nephrol 16:496–506

    PubMed  Google Scholar 

  26. Cole EH, Johnston O, Rose CL, Gill JS (2008) Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival. Clin J Am Soc Nephrol 3:814–821

    PubMed  PubMed Central  Google Scholar 

  27. Pascual J, Zamora J, Galeano C, Royuela A, Quereda C (2009) Steroid avoidance or withdrawal for kidney transplant recipients. Cochrane Database Syst Rev 1:CD005632

    Google Scholar 

  28. Heisel O, Heisel R, Balshaw R, Keown P (2004) New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant 4:583–595

    PubMed  Google Scholar 

  29. Vincenti F, Friman S, Scheuermann E et al (2007) Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 7:1506–1514

    CAS  PubMed  Google Scholar 

  30. Ghisdal L, Van Laecke S, Abramowicz MJ (2012) New-onset diabetes after renal transplantation: risk assessment and management. Diabetes Care 35:181–188

    CAS  PubMed  Google Scholar 

  31. Satterthwaite R, Aswad S, Sunga V et al (1998) Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine. Transplantation 65:446–449

    CAS  PubMed  Google Scholar 

  32. Xue W, Zhang Q, Xu Y, Wang W, Zhang X, Hu X (2014) Effects of tacrolimus and cyclosporine treatment on metabolic syndrome and cardiovascular risk factors after renal transplantation: a meta-analysis. Chin Med J 127:2376–2381

    CAS  PubMed  Google Scholar 

  33. Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J (2002) A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation 73:775–782

    CAS  PubMed  Google Scholar 

  34. Miller LW (2002) Cardiovascular toxicities of immunosuppressive agents. Am J Transplant 2:807–818

    CAS  PubMed  Google Scholar 

  35. Holdaas H, Fellström B, Cole E et al (2005) Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant 5:2929–2936

    CAS  PubMed  Google Scholar 

  36. Holdaas H, Fellström B, Jardine AG et al (2005) Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation. Nephrol Dial Transplant 20:974–980

    CAS  PubMed  Google Scholar 

  37. Opelz G, Wujciak T, Ritz E (1998) Association of chronic kidney graft failure with recipient blood pressure. Kidney Int 53:217–222

    CAS  PubMed  Google Scholar 

  38. Kasiske BL, Anjum S, Shah R et al (2004) Hypertension after kidney transplantation. Am J Kidney Dis 43:1071–1081

    PubMed  Google Scholar 

  39. Opelz G, Döhler B, Collaborative Transplant Study (2005) Improved long-term outcomes after renal transplantation associated with blood pressure control. Am J Transplant 5:2725–2731

    PubMed  Google Scholar 

  40. Klawitter J, Nashan B, Christians U (2015) Everolimus and sirolimus in transplantation-related but different. Expert Opin Drug Saf 14:1055–1070

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Sawinski D, Trofe-Clark J, Leas B et al (2016) Calcineurin inhibitor minimization, conversion, withdrawal, and avoidance strategies in renal transplantation: a systematic review and meta-analysis. Am J Transplant 16:2117–2138

    CAS  PubMed  Google Scholar 

  42. Oberbauer R, Kreis H, Johnson RW et al (2003) Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation 76:364–370

    CAS  PubMed  Google Scholar 

  43. Ekberg H, Tedesco-Silva H, Demirbas A et al (2007) Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 357:2562–2575

    CAS  PubMed  Google Scholar 

  44. Flechner SM, Glyda M, Cockfield S et al (2011) The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant 11:1633–1644

    CAS  PubMed  Google Scholar 

  45. Flechner SM, Gurkan A, Hartmann A et al (2013) A randomized, open-label study of sirolimus versus cyclosporine in primary de novo renal allograft recipients. Transplantation 95:1233–1241

    CAS  PubMed  Google Scholar 

  46. Budde K, Zeier M, Witzke O et al (2017) Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial. Nephrol Dial Transplant 32:1060–1070

    CAS  PubMed  Google Scholar 

  47. Sommerer C, Duerr M, Witzke O et al (2018) Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy. Am J Transplant 18:2965–2976

    CAS  PubMed  Google Scholar 

  48. Budde K, Lehner F, Sommerer C et al (2015) Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study. Am J Transplant 15:119–128

    CAS  PubMed  Google Scholar 

  49. Mjörnstedt L, Sørensen SS, von Zur Mühlen B et al (2012) Improved renal function after early conversion from a calcineurin inhibitor to everolimus: a randomized trial in kidney transplantation. Am J Transplant 12:2744–2753

    PubMed  Google Scholar 

  50. Holdaas H, Rostaing L, Serón D et al (2011) Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study. Transplantation 92:410–418

    CAS  PubMed  Google Scholar 

  51. de Fijter JW, Holdaas H, Øyen O et al (2017) Early conversion from calcineurin inhibitor- to everolimus-based therapy following kidney transplantation: results of the randomized ELEVATE trial. Am J Transplant 17:1853–1867

    PubMed  Google Scholar 

  52. Tedesco Silva H Jr, Cibrik D, Johnston T et al (2010) Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant 10:1401–1413

    PubMed  Google Scholar 

  53. Langer RM, Hené R, Vitko S et al (2012) Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation. Transpl Int 25:592–602

    CAS  PubMed  Google Scholar 

  54. Salvadori M, Scolari MP, Bertoni E et al (2009) Everolimus with very low-exposure cyclosporine a in de novo kidney transplantation: a multicenter, randomized, controlled trial. Transplantation 88:1194–1202

    CAS  PubMed  Google Scholar 

  55. Bemelman FJ, de Fijter JW, Kers J et al (2017) Early conversion to prednisolone/everolimus as an alternative weaning regimen associates with beneficial renal transplant histology and function: the randomized-controlled MECANO trial. Am J Transplant 17:1020–1030

    CAS  PubMed  Google Scholar 

  56. Pascual J, Berger SP, Witzke O et al (2018) Everolimus with reduced calcineurin inhibitor exposure in renal transplantation. J Am Soc Nephrol 29:1979–1991

    CAS  PubMed  PubMed Central  Google Scholar 

  57. Furian L, Silvestre C, Vallese L et al (2014) Everolimus associated with low-dose calcineurin inhibitors, an option in kidney transplant recipients of very old donors. Transplant Proc 46:3390–3395

    CAS  PubMed  Google Scholar 

  58. Karpe KM, Talaulikar GS, Walters GD (2017) Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients. Cochrane Database Syst Rev 7:CD006750

    PubMed  Google Scholar 

  59. Houben AJHM, Martens RJH, Stehouwer CDA (2017) Assessing microvascular function in humans from a chronic disease perspective. J Am Soc Nephrol 28:3461–3472

    CAS  PubMed  PubMed Central  Google Scholar 

  60. Valdivielso JM, Betriu A, Martinez-Alonso M, Arroyo D, Bermudez-Lopez M, Fernandez E (2017) Factors predicting cardiovascular events in chronic kidney disease patients. Role of subclinical atheromatosis extent assessed by vascular ultrasound. PLoS ONE 12:e0186665

    PubMed  PubMed Central  Google Scholar 

  61. Hernández D, Triñanes J, Armas AM (2017) Vascular damage and kidney transplant outcomes: an unfriendly and harmful link. Am J Med Sci 354:7–16

    PubMed  Google Scholar 

  62. Matsuzawa Y, Lerman A (2014) Endothelial dysfunction and coronary artery disease: assessment, prognosis, and treatment. Coron Artery Dis 25:713–724

    PubMed  PubMed Central  Google Scholar 

  63. Bonetti PO, Lerman LO, Lerman A (2003) Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 23:168–175

    CAS  PubMed  Google Scholar 

  64. Rodrigues-Diez R, González-Guerrero C, Ocaña-Salceda C et al (2016) Calcineurin inhibitors cyclosporine A and tacrolimus induce vascular inflammation and endothelial activation through TLR4 signaling. Sci Rep 6:27915

    CAS  PubMed  PubMed Central  Google Scholar 

  65. Shing CM, Fassett RG, Brown L, Coombes JS (2012) The effects of immunosuppressants on vascular function, systemic oxidative stress and inflammation in rats. Transpl Int 25:337–346

    CAS  PubMed  Google Scholar 

  66. Sitia S, Tomasoni L, Atzeni F et al (2010) From endothelial dysfunction to atherosclerosis. Autoimmun Rev 9:830–834

    CAS  PubMed  Google Scholar 

  67. Rubinshtein R, Kuvin JT, Soffler M et al (2010) Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. Eur Heart J 31:1142–1148

    PubMed  Google Scholar 

  68. Shechter M, Issachar A, Marai I et al (2009) Long-term association of brachial artery flow-mediated vasodilation and cardiovascular events in middle-aged subjects with no apparent heart disease. Int J Cardiol 134:52–58

    PubMed  Google Scholar 

  69. Kurdi A, De Meyer GRY, Martinet W (2016) Potential therapeutic effects of mTOR inhibition in atherosclerosis. Br J Clin Pharmacol 82:1267–1279

    CAS  PubMed  Google Scholar 

  70. Baetta R, Granata A, Canavesi M et al (2009) Everolimus inhibits monocyte/macrophage migration in vitro and their accumulation in carotid lesions of cholesterol-fed rabbits. J Pharmacol Exp Ther 328:419–425

    CAS  PubMed  Google Scholar 

  71. Chen WQ, Zhong L, Zhang L et al (2009) Oral rapamycin attenuates inflammation and enhances stability of atherosclerotic plaques in rabbits independent of serum lipid levels. Br J Pharmacol 156:941–951

    CAS  PubMed  PubMed Central  Google Scholar 

  72. Naoum JJ, Woodside KJ, Zhang S, Rychahou PG, Hunter GC (2005) Effects of rapamycin on the arterial inflammatory response in atherosclerotic plaques in Apo-E knockout mice. Transplant Proc 37:1880–1884

    CAS  PubMed  Google Scholar 

  73. Avery RK (2003) Cardiac-allograft vasculopathy. N Engl J Med 349:829–830

    PubMed  Google Scholar 

  74. Jansen MA, Otten HG, de Weger RA, Huibers MM (2015) Immunological and fibrotic mechanisms in cardiac allograft vasculopathy. Transplantation 99:2467–2475

    CAS  PubMed  Google Scholar 

  75. Langstraat M, Musters KJS, Manintveld O, Masetti M, Potena L (2018) Coronary artery disease in heart transplantation: new concepts for an old disease. Transpl Int 31:787–827

    PubMed  Google Scholar 

  76. Eisen HJ, Kobashigawa J, Starling RC et al (2013) Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial. Am J Transplant 13:1203–1216

    CAS  PubMed  Google Scholar 

  77. Andreassen AK, Andersson B, Gustafsson F et al (2016) Everolimus initiation with early calcineurin inhibitor withdrawal in de novo heart transplant recipients: three-year results from the randomized SCHEDULE study. Am J Transplant 16:1238–1247

    CAS  PubMed  Google Scholar 

  78. Masetti M, Potena L, Nardozza M et al (2013) Differential effect of everolimus on progression of early and late cardiac allograft vasculopathy in current clinical practice. Am J Transplant 13:1217–1226

    CAS  PubMed  Google Scholar 

  79. Vlachopoulos C, Aznaouridis K, Stefanadis C (2010) Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 55:1318–1327

    PubMed  Google Scholar 

  80. Ben-Shlomo Y, Spears M, Boustred C et al (2014) Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. J Am Coll Cardiol 63:636–646

    PubMed  Google Scholar 

  81. Seckinger J, Sommerer C, Hinkel UP, Hoffmann O, Zeier M, Schwenger V (2008) Switch of immunosuppression from cyclosporine A to everolimus: impact on pulse wave velocity in stable de-novo renal allograft recipients. J Hypertens 26:2213–2219

    CAS  PubMed  Google Scholar 

  82. Joannidès R, Monteil C, de Ligny BH (2011) Immunosuppressant regimen based on sirolimus decreases aortic stiffness in renal transplant recipients in comparison to cyclosporine. Am J Transplant 11:2414–2422

    PubMed  Google Scholar 

  83. Dumor K, Shoemaker-Moyle M, Nistala R, Whaley-Connell A (2018) Arterial stiffness in hypertension: an update. Curr Hypertens Rep 20:72

    PubMed  Google Scholar 

  84. Zhao Y, Zhao MM, Cai Y et al (2015) Mammalian target of rapamycin signaling inhibition ameliorates vascular calcification via Klotho upregulation. Kidney Int 88:711–721

    CAS  PubMed  Google Scholar 

  85. Holdaas H, de Fijter JW, Cruzado JM (2017) Cardiovascular parameters to 2 years after kidney transplantation following early switch to everolimus without calcineurin inhibitor therapy: an analysis of the randomized ELEVATE study. Transplantation 101:2612–2620

    PubMed  Google Scholar 

  86. Paoletti E, Gherzi M, Amidone M, Massarino F, Cannella G (2009) Association of arterial hypertension with renal target organ damage in kidney transplant recipients: the predictive role of ambulatory blood pressure monitoring. Transplantation 87:1864–1869

    PubMed  Google Scholar 

  87. Minutolo R, Agarwal R, Borrelli S et al (2011) Prognostic role of ambulatory blood pressure measurement in patients with nondialysis chronic kidney disease. Arch Intern Med 171:1090–1098

    PubMed  Google Scholar 

  88. Rigatto C, Foley R, Jeffery J, Negrijn C, Tribula C, Parfrey P (2003) Electrocardiographic left ventricular hypertrophy in renal transplant recipients: prognostic value and impact of blood pressure and anemia. J Am Soc Nephrol 14:462–468

    PubMed  Google Scholar 

  89. Paoletti E, Amidone M, Cassottana P, Gherzi M, Marsano L, Cannella G (2008) Effect of sirolimus on left ventricular hypertrophy in kidney transplant recipients: a 1-year nonrandomized controlled trial. Am J Kidney Dis 52:324–330

    CAS  PubMed  Google Scholar 

  90. Raichlin E, Chandrasekaran K, Kremers WK et al (2008) Sirolimus as primary immunosuppressant reduces left ventricular mass and improves diastolic function of the cardiac allograft. Transplantation 86:1395–1400

    CAS  PubMed  Google Scholar 

  91. Sciarretta S, Volpe M, Sadoshima J (2014) Mammalian target of rapamycin signaling in cardiac physiology and disease. Circ Res 114:549–564

    CAS  PubMed  PubMed Central  Google Scholar 

  92. Siedlecki AM, Jin X, Muslin AJ (2009) Uremic cardiac hypertrophy is reversed by rapamycin but not by lowering of blood pressure. Kidney Int 75:800–808

    CAS  PubMed  PubMed Central  Google Scholar 

  93. Paoletti E, Marsano L, Bellino D et al (2012) Effect of everolimus on left ventricular hypertrophy of de novo kidney transplant recipients: a 1 year, randomized, controlled trial. Transplantation 93:503–508

    CAS  PubMed  Google Scholar 

  94. Hernández D, Ruiz-Esteban P, Gaitán D et al (2014) Regression of cardiac growth in kidney transplant recipients using anti-m-TOR drugs plus RAS blockers: a controlled longitudinal study. BMC Nephrol 15:65

    PubMed  PubMed Central  Google Scholar 

  95. Murbraech K, Holdaas H, Massey R et al (2014) Cardiac response to early conversion from calcineurin inhibitor to everolimus in renal transplant recipients: an echocardiographic substudy of the randomized controlled CENTRAL trial. Transplantation 97:184–188

    CAS  PubMed  Google Scholar 

  96. Paoletti E (2018) mTOR inhibition and cardiovascular diseases: cardiac hypertrophy. Transplantation 102(2S Suppl):S41–S43

    CAS  PubMed  Google Scholar 

  97. Vergès B, Cariou B (2015) mTOR inhibitors and diabetes. Diabetes Res Clin Pract 110:101–108

    PubMed  Google Scholar 

  98. Johnston O, Rose CL, Webster AC, Gill JS (2008) Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 19:1411–1418

    PubMed  PubMed Central  Google Scholar 

  99. Peddi VR, Wiseman A, Chavin K, Slakey D (2013) Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation. Transplant Rev (Orlando) 27:97–107

    Google Scholar 

  100. Murakami N, Riella LV, Funakoshi T (2014) Risk of metabolic complications in kidney transplantation after conversion to mTOR inhibitor: a systematic review and meta-analysis. Am J Transplant 14:2317–2327

    CAS  PubMed  Google Scholar 

  101. Kälble F, Seckinger J, Schaier M et al (2017) Switch to an everolimus-facilitated cyclosporine A sparing immunosuppression improves glycemic control in selected kidney transplant recipients. Clin Transplant. https://doi.org/10.1111/ctr.13024

    Article  PubMed  Google Scholar 

  102. Holdaas H, Potena L, Saliba F (2015) mTOR inhibitors and dyslipidemia in transplant recipients: a cause for concern? Transplant Rev (Orlando) 29:93–102

    Google Scholar 

  103. Vitko S, Tedesco H, Eris J et al (2004) Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 4:626–635

    CAS  PubMed  Google Scholar 

  104. Kurdi A, Martinet W, De Meyer GRY (2018) mTOR inhibition and cardiovascular diseases: dyslipidemia and atherosclerosis. Transplantation 102(2S Suppl 1):S44–S46

    CAS  PubMed  Google Scholar 

  105. Wanitchanont A, Somparn P, Vadcharavivad S et al (2014) Effects of atorvastatin on the pharmacokinetics of everolimus among kidney transplant recipients. Transplant Proc 46:418–421

    CAS  PubMed  Google Scholar 

  106. Ferri N, Granata A, Pirola C et al (2008) Fluvastatin synergistically improves the antiproliferative effect of everolimus on rat smooth muscle cells by altering p27Kip1/cyclin E expression. Mol Pharmacol 74:144–153

    CAS  PubMed  Google Scholar 

  107. El Ters M, Grande JP, Keddis MT et al (2013) Kidney allograft survival after acute rejection, the value of follow-up biopsies. Am J Transplant 13:2334–2341

    PubMed  Google Scholar 

  108. Vereerstraeten P, Abramowicz D, de Pauw L, Kinnaert P (1997) Absence of deleterious effect on long-term kidney graft survival of rejection episodes with complete functional recovery. Transplantation 63:1739–1743

    CAS  PubMed  Google Scholar 

  109. de Mattos AM, Prather J, Olyaei AJ et al (2006) Cardiovascular events following renal transplantation: role of traditional and transplant-specific risk factors. Kidney Int 70:757–764

    PubMed  Google Scholar 

  110. Kasiske BL, Chakkera HA, Roel J (2000) Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 11:1735–1743

    CAS  PubMed  Google Scholar 

  111. Shihab F, Qazi Y, Mulgaonkar S et al (2017) Association of clinical events with everolimus exposure in kidney transplant patients receiving low doses of tacrolimus. Am J Transplant 17:2363–2371

    CAS  PubMed  PubMed Central  Google Scholar 

  112. van Gelder T, Fischer L, Shihab F, Shipkova M (2017) Optimizing everolimus exposure when combined with calcineurin inhibitors in solid organ transplantation. Transplant Rev (Orlando) 31:151–157

    Google Scholar 

  113. Flechner SM, Kurian SM, Solez K et al (2004) De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 4:1776–1785

    CAS  PubMed  Google Scholar 

  114. Budde K, Becker T, Arns W et al (2011) Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 377:837–847

    CAS  PubMed  Google Scholar 

  115. Lebranchu Y, Thierry A, Toupance O et al (2009) Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am J Transplant 9:1115–1123

    CAS  PubMed  Google Scholar 

  116. Ponticelli C, Salvadori M, Scolari MP et al (2011) Everolimus and minimization of cyclosporine in renal transplantation: 24-month follow-up of the EVEREST study. Transplantation 91:e72–e73

    PubMed  Google Scholar 

  117. Fernández-Fresnedo G, Plaza JJ, Sánchez-Plumed J, Sanz-Guajardo A, Palomar-Fontanet R, Arias M (2004) Proteinuria: a new marker of long-term graft and patient survival in kidney transplantation. Nephrol Dial Transplant 19(Suppl 3):iii47–51

    PubMed  Google Scholar 

  118. Amer H, Cosio FG (2009) Significance and management of proteinuria in kidney transplant recipients. J Am Soc Nephrol 20:2490–2492

    PubMed  Google Scholar 

  119. Hernández D, Pérez G, Marrero D et al (2012) Early association of low-grade albuminuria and allograft dysfunction predicts renal transplant outcomes. Transplantation 93:297–303

    PubMed  Google Scholar 

  120. Roodnat JI, Mulder PG, Rischen-Vos J et al (2001) Proteinuria after renal transplantation affects not only graft survival but also patient survival. Transplantation 72:438–444

    CAS  PubMed  Google Scholar 

  121. Halimi JM, Matthias B, Al-Najjar A et al (2007) Respective predictive role of urinary albumin excretion and nonalbumin proteinuria on graft loss and death in renal transplant recipients. Am J Transplant 7:2775–2781

    PubMed  Google Scholar 

  122. Weiner DE, Park M, Tighiouart H et al (2018) Albuminuria and allograft failure, cardiovascular disease events, and all-cause death in stable kidney transplant recipients: a cohort analysis of the FAVORIT trial. Am J Kidney Dis. https://doi.org/10.1053/j.ajkd.2018.05.015

    Article  PubMed  PubMed Central  Google Scholar 

  123. Izzedine H, Brocheriou I, Frances C (2005) Post-transplantation proteinuria and sirolimus. N Engl J Med 353:2088–2089

    CAS  PubMed  Google Scholar 

  124. Somlo S, Mundel P (2000) Getting a foothold in nephrotic syndrome. Nat Genet 24:333–335

    CAS  PubMed  Google Scholar 

  125. Tryggvason K, Patrakka J, Wartiovaara J (2006) Hereditary proteinuria syndromes and mechanisms of proteinuria. N Engl J Med 354:1387–1401

    CAS  PubMed  Google Scholar 

  126. Stallone G, Infante B, Pontrelli P et al (2011) Sirolimus and proteinuria in renal transplant patients: evidence for a dose-dependent effect on slit diaphragm-associated proteins. Transplantation 91:997–1004

    CAS  PubMed  Google Scholar 

  127. Letavernier E, Bruneval P, Mandet C et al (2007) High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol 2:326–333

    CAS  PubMed  Google Scholar 

  128. Bonegio RGB, Fuhro R, Wang Z et al (2005) Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol 16:2063–2072

    CAS  PubMed  Google Scholar 

  129. Torras J, Herrero-Fresneda I, Gulias O et al (2009) Rapamycin has dual opposing effects on proteinuric experimental nephropathies: is it a matter of podocyte damage? Nephrol Dial Transplant 24:3632–3640

    CAS  PubMed  Google Scholar 

  130. Pallet N, Thervet E, Le Corre D et al (2005) Rapamycin inhibits human renal epithelial cell proliferation: effect on cyclin D3 mRNA expression and stability. Kidney Int 67:2422–2433

    CAS  PubMed  Google Scholar 

  131. Stallone G, Infante B, Grandaliano G, Gesualdo L (2009) Management of side effects of sirolimus therapy. Transplantation 87(8 Suppl):S23–S26

    CAS  PubMed  Google Scholar 

  132. Mallat SG, Tanios BY, Itani HS et al (2017) CMV and BKPyV infections in renal transplant recipients receiving an mTOR inhibitor-based regimen versus a CNI-based regimen: a systematic review and meta-analysis of randomized, controlled trials. Clin J Am Soc Nephrol 12:1321–1336

    CAS  PubMed  PubMed Central  Google Scholar 

  133. Lim WH, Russ GR, Wong G, Pilmore H, Kanellis J, Chadban SJ (2017) The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine. Kidney Int 91:954–963

    CAS  PubMed  Google Scholar 

  134. Wolf S, Hoffmann VS, Habicht A et al (2018) Effects of mTOR-Is on malignancy and survival following renal transplantation: a systematic review and meta-analysis of randomized trials with a minimum follow-up of 24 months. PLoS ONE 13:e0194975

    PubMed  PubMed Central  Google Scholar 

  135. Johnson SC, Rabinovitch PS, Kaeberlein M (2013) mTOR is a key modulator of ageing and age related disease. Nature 493:338–345

    CAS  PubMed  PubMed Central  Google Scholar 

  136. Donato AJ, Morgan RG, Walker AE, Lesniewski LA (2015) Cellular and molecular biology of aging endothelial cells. J Mol Cell Cardiol 89:122–135

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank Gayle Robins, independent medical writer, who provided editorial assistance and journal styling services prior to submission on behalf of Springer Healthcare Communications. Editorial services were funded by Novartis Farma, Italy.

Collaborators We would like to thank experts in the field of transplantation who participated in the round-table discussions of the ENTROPIA Project: Andrea Ambrosini, Azienda Ospedaliera Fondazione Macchi, Varese, Italy; Lorenzo Arnaboldi, Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Milan, Italy; Diego Bellino, Division of Nephrology, Dialysis, and Transplantation, University of Genoa, IRCCS Azienda Ospedaliera Universitaria San Martino-IST, Genoa, Italy; Luigi Boschiero, Azienda Ospedaliera Borgo Trento, Verona, Italy; Rossana Caldara, IRCCS San Raffaele, Milan, Italy; Manuela Cannone, Department of Nephrology, Dialysis and Transplantation, International Renal Research Institute of Vicenza (IRRIV), San Bortolo Hospital, Vicenza, Italy; Mario Carmellini, Department of Medical, Surgical and Neuroscience, Division of Kidney Transplantation, Policlinico Santa Maria alle Scotte, University of Siena, Siena, Italy; Rosa Carrano, Department of Public Health, Section of Nephrology and Renal Transplantation, "Federico II" University, Naples, Italy; Matteo Ciancio Manuelli, UOSD Chirurgia d’Urgenza, Policlinico Tor Vergata, Rome Italy; Marco De Cicco, Azienda Ospedaliera Fondazione Macchi, Varese, Italy; Paride De Rosa, General Surgery and Transplantation Unit, "San Giovanni di Dio e Ruggi D'Aragona" University Hospital, Scuola Medica Salernitana, Salerno, Italy; Stefano Federico, Department of Public Health, Section of Nephrology and Renal Transplantation, "Federico II" University, Naples, Italy; Guido Garosi, Nephrology, Dialysis and Transplantation, Azienda Ospedaliera Universitaria Senese, Siena, Italy; Massimo Iappelli, Nephrology and Transplant Unit, A.O.S. Camillo-Forlanini, Roma, Italy; Giuseppe Iaria, Liver and Kidney Transplant Centre, University of Rome Tor Vergata, Rome, Italy; Stefania Mastrosimone, Nephrology and Dialysis Department, Ca' Foncello Hospital, Treviso, Italy; Enrico Eugenio Minetti, Azienda Ospedaliero Universitaria Careggi, Florence, Italy; Giovanni Piotti, Kidney and Pancreas Transplantation Unit, University Hospital of Parma, Parma, Italy; Gianbenedetto Piredda, UOC Nefrologia, Azienda Ospedaliera Brotzu, Cagliari, Italy; Franco Pisani, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy; Luca Poli, Organ Transplant Unit Paride Stefanini, Sapienza University of Rome, Rome, Italy; Renzo Pretagostini, Department of General Surgery and Organ Transplantation, Sapienza University, Umberto I Hospital, Rome, Italy; Roberto Pulizzi, Nephrology and Dialysis, Policlinico di Modena, Modena, Italy; Teresa Rampino, IRCCS Policlinico San Matteo, Pavia, Italy; Andrea Ranghino, Nephrology, Dialysis and Kidney Transplant Unit, Ospedali Riuniti, Ancona, Italy; Massimo Sabbatini, Department of Public Health, Section of Nephrology and Renal Transplantation, "Federico II" University, Naples, Italy; Angelo Saracino, Centro Regionale Trapianti, Ospedale Madonna delle Grazie Matera, Italy; Paola Todeschini, Department of Nephrology and Dialysis, S. Orsola Hospital, Bologna, Italy; Daniela Vicedomini, General Surgery and Transplantation Unit, "San Giovanni di Dio e Ruggi D'Aragona" University Hospital, Scuola Medica Salernitana, Salerno, Italy; Valentina Vinti, Nephrology and Transplantation, P.O. "Civico, Di Cristina e Benfratelli", Palermo, Italy; Gianluigi Zaza, Department of Medicine, Renal Unit, University and Hospital Trust of Verona, Verona, Italy.

Author information

Authors and Affiliations

  1. Nephrology, Dialysis, and Transplantation, Policlinico San Martino - Università di Genova, Largo Rosanna Benzi, 10, 16132, Genoa, GE, Italy

    Ernesto Paoletti & Elisabetta Bussalino

  2. Renal Transplantation Unit, Fondazione Policlinico Universitario A. Gemelli, Rome, Italy

    Franco Citterio

  3. Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Milan, Italy

    Alberto Corsini

  4. IRCCS Multimedica, Milan, Italy

    Alberto Corsini

  5. Cardiovascular Department, University of Bologna, Bologna, Italy

    Luciano Potena

  6. Kidney and Pancreas Transplantation Unit, Department of Surgical, Oncological and Gastroenterological Sciences, University of Padua, Padua, Italy

    Paolo Rigotti

  7. Division of Nephrology, University of Brescia and Spedali Civili General Hospital, Brescia, Italy

    Silvio Sandrini

  8. Nephrology, Dialysis and Transplantation Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy

    Giovanni Stallone

Authors
  1. Ernesto Paoletti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Franco Citterio
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alberto Corsini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Luciano Potena
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Paolo Rigotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Silvio Sandrini
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Elisabetta Bussalino
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Giovanni Stallone
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

ENTROPIA Project

  • Andrea Ambrosini
  • , Lorenzo Arnaboldi
  • , Diego Bellino
  • , Luigi Boschiero
  • , Rossana Caldara
  • , Manuela Cannone
  • , Mario Carmellini
  • , Rosa Carrano
  • , Matteo Ciancio Manuelli
  • , Marco De Cicco
  • , Paride De Rosa
  • , Stefano Federico
  • , Guido Garosi
  • , Massimo Iappelli
  • , Giuseppe Iaria
  • , Stefania Mastrosimone
  • , Enrico Eugenio Minetti
  • , Giovanni Piotti
  • , Gianbenedetto Piredda
  • , Franco Pisani
  • , Luca Poli
  • , Renzo Pretagostini
  • , Roberto Pulizzi
  • , Teresa Rampino
  • , Andrea Ranghino
  • , Massimo Sabbatini
  • , Angelo Saracino
  • , Paola Todeschini
  • , Daniela Vicedomini
  • , Valentina Vinti
  •  & Gianluigi Zaza

Contributions

EP, FC, AC, LP, PR, SS and GS were the members of the ENTROPIA expert panel. All the Authors performed the literature search, wrote and revised the paper and approved the final version before submission.

Corresponding author

Correspondence to Ernesto Paoletti.

Ethics declarations

Conflict of interest

EP, FC, AC, and GS received honoraria and consultant fees from Novartis Farma; PR, SS, received honoraria and consultant fees from Astellas and Novartis; LP received honoraria and consultant fees from Novartis and Sandoz; EB declares no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Paoletti, E., Citterio, F., Corsini, A. et al. Everolimus in kidney transplant recipients at high cardiovascular risk: a narrative review. J Nephrol 33, 69–82 (2020). https://doi.org/10.1007/s40620-019-00609-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40620-019-00609-y

Keywords

Search

Navigation